ArticleClinical therapeutics2011
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
Sreeneeranj Kasichayanula et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this papertrialcites it